CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Exclusion Criteria

• •Endocrine or acinar pancreatic carcinoma
• •Previous radiotherapy for cerebral metastases, central nervous system (CNS) or epidural tumor
• •Prior treatment with any chemotherapy for metastatic disease from pancreatic cancer
• •Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 4 weeks prior to initiation of CPI-613 treatment
• •Serious medical illness that would potentially increase patients' risk for toxicity
• •Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease)
• •Pregnant women, or women of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown)
• •Lactating females
• •Fertile men unwilling to practice contraceptive methods during the study period
• •Life expectancy less than 2 months
• •Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients
• •Unwilling or unable to follow protocol requirements
• •Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction, or symptomatic congestive heart failure
• •Patients with a history of myocardial infarction that is \< 3 months prior to registration
• •Evidence of active infection, or serious infection within the past month
• •Patients with known human immunodeficiency virus (HIV) infection
• •Patients who have received immunotherapy of any type within the past 4 weeks prior to initiation of CPI-613 treatment
• •Requirement for immediate palliative treatment of any kind including surgery
• •Patients that have received a chemotherapy regimen with stem cell support in the previous 6 months
• •Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of the patient